MGC Pharmaceuticals, LTD. (ASX: MXC) (OTC: MGCLF) Cannabis-based pharmaceuticals for major markets (revenue positive)



Roby Zomer, CEO








MGC Pharmaceuticals, LTD. (ASX: MXC) (OTC: MGCLF) CEO Interview with Roby Zomer, discussing the company’s vertically integrated “Seed-to Pharmacy” strategy, and product pipeline. The company has three products in the pipeline, targeting: drug-resistant epliepsy, dementia, and Chron’s disease/Irritable Bowel Disease (IBS).

MGC Pharmaceuticals has recently started generating revenues from sales of CannEpil, for treating drug-resistant epilepsy in Australia and UK via the “authorised prescriber” program, prior to final regulatory approval, expected in 3-4 years. The immediately addressable market opportunity is potentially 700,000 patients at $9,000 per year.

Other topics discussed in this interview include: Overview of European manufacturing and distribution operations, and more.


Investor Presentation

Mgc pharma
Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.